Dr. Doug Manion As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the activity of biologics, Dr. Doug Manion has a...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Novavax sets first-in-human trial for coronavirus vaccine candidate in mid-May
Novavax (NASDAQ:NVAX) identified a coronavirus vaccine candidate, NVX-CoV2373, using its nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’s Matrix-M adjuvant will be incorporated...
FDA clears Mesoblast IND for remestemcel-L in ARDS caused by COVID-19
Mesoblast (NASDAQ:MESO; ASX:MSB) received clearance from the FDA for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intravenous infusions of its allogeneic...
SVB Leerink slashes Millendo Therapeutics PT to $5 from $24
SVB Leerink hammered the price target of Millendo Therapeutics (NASDAQ:MLND) to $5 from $24, but maintained its “outperform” rating, after the company’s Phase 2b trial of livoletide for the treatment of Prader-Willi...
Maxim ups AIM ImmunoTech PT to $5 from $2
Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...
HCW starts IDEAYA Biosciences at buy; PT $13
H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...
IntelGenx adjusts VersaFilm business strategy
IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) unveiled a series of initiatives aimed at helping the company address, and satisfactorily respond to, the complete response letter that it recently received from the FDA...
SVB Leerink starts Imara at OP; PT $25
SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...
Profound Medical launches TULSA patient website in U.S.
Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...
Echelon ascribes Top Pick status to Centric Health, Protech Home Medical
Echelon Wealth Partners ascribed Top Pick status to Centric Health (TSX:CHH) and Protech Home Medical (TSXV:PTQ), while maintaining “buy” ratings and price targets of 25 cents and $2.50, respectively. Shares of Centric...
Just a few of the companies we’ve highlighted along the way
